David Santos

David Santos was appointed Executive Vice President and Chief Commercial Offcer in August 2020. Mr. Santos joined Rigel from Jazz Pharmaceuticals, where he held the role of Hematology/Oncology Business Unit Head, responsible for leading US commercialization of the oncology portfolio. During his tenure at Jazz, he successfully grew the business unit through three launches to eventually have four promoted products in the leukemia, transplant and lung cancer markets. Prior to joining Jazz, Mr. Santos served as Vice President of Sales and Marketing for Medivation (now Pfizer), responsible for commercializing Xtandi@ for metastatic prostate cancer, and Vice President, Kinase Inhibitor Franchise for Onyx (now Amgen), responsible for leading sales and marketing efforts with Nexavar@ and Stivarga@. Before his work at Onyx, Mr. Santos served for nearly 9 years in roles of increasing responsibility at Genentech, Inc. (now a member of the Roche Group), where he launched and held key commercial leadership roles on several successful brands, including Avastin@, Herceptin@ and Tarceva@. Mr. Santos also held marketing and sales roles at Lilly Oncology and Bristol-Myers Squibb, where he started his pharmaceutical sales career. He received his BS in Chemistry from St. Louis University.